Stoneridge Investment Partners LLC raised its position in Hologic, Inc. (NASDAQ:HOLX) by 45.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 229,775 shares of the medical equipment provider’s stock after purchasing an additional 72,246 shares during the quarter. Hologic accounts for approximately 1.3% of Stoneridge Investment Partners LLC’s holdings, making the stock its 17th biggest holding. Stoneridge Investment Partners LLC owned approximately 0.08% of Hologic worth $8,430,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Koch Industries Inc. raised its position in Hologic by 15,554.1% in the 2nd quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock worth $1,125,000 after purchasing an additional 1,142,138 shares during the period. Picton Mahoney Asset Management increased its position in shares of Hologic by 8.1% during the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock worth $2,593,000 after acquiring an additional 4,300 shares during the period. Russell Investments Group Ltd. increased its position in shares of Hologic by 229.7% during the second quarter. Russell Investments Group Ltd. now owns 1,059,586 shares of the medical equipment provider’s stock worth $48,100,000 after acquiring an additional 738,215 shares during the period. Swiss National Bank increased its position in shares of Hologic by 12.8% during the second quarter. Swiss National Bank now owns 1,159,424 shares of the medical equipment provider’s stock worth $52,615,000 after acquiring an additional 131,300 shares during the period. Finally, Rhumbline Advisers increased its position in shares of Hologic by 1.4% during the second quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock worth $24,889,000 after acquiring an additional 7,727 shares during the period. 96.04% of the stock is currently owned by institutional investors.

In other news, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Lawrence M. Levy sold 7,138 shares of the stock in a transaction that occurred on Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,873 shares of company stock worth $898,754. Insiders own 0.79% of the company’s stock.

Hologic, Inc. (NASDAQ:HOLX) traded down $0.50 during midday trading on Tuesday, hitting $39.06. 2,675,809 shares of the stock were exchanged, compared to its average volume of 3,020,000. The company has a current ratio of 0.85, a quick ratio of 0.65 and a debt-to-equity ratio of 0.78. Hologic, Inc. has a 1 year low of $35.76 and a 1 year high of $46.80. The company has a market capitalization of $10,930.00, a P/E ratio of 19.39, a PEG ratio of 1.74 and a beta of 0.93.

A number of brokerages have recently commented on HOLX. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $45.00 target price (down from $50.00) on shares of Hologic in a research report on Wednesday, August 9th. BidaskClub lowered shares of Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Barclays PLC reaffirmed an “equal weight” rating and set a $51.00 target price (down from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Needham & Company LLC reaffirmed a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Finally, Zacks Investment Research raised shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nine have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $47.77.

COPYRIGHT VIOLATION WARNING: “Hologic, Inc. (HOLX) Position Increased by Stoneridge Investment Partners LLC” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/07/hologic-inc-holx-position-increased-by-stoneridge-investment-partners-llc.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.